Company news: Alembic Pharmaceuticals

| Updated on October 24, 2019

Alembic Pharmaceuticals’s joint venture Aleor Dermaceuticals has received an approval from the US Food & Drug Administration for its Abbreviated New Drug Application Desonide ointment, 0.05%. The approved ANDA is therapeutically equivalent to Perrigo New York, Inc’s ointment. The drug is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. The ointment has an estimated market size of $13 million in calendar 2018, according to IQVIA. Shares of Alembic closed 1.8 per cent higher at ₹546.95 on the BSE.

Published on October 24, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like